BibbInstruments

BibbInstruments Equity

The The Equity of BibbInstruments (BIBB.SL) as of Oct 19, 2026 is 37.63 M SEK. In the previous year, The Equity was 28.38 M SEK — a change of 32.61% (higher).

Equity

37.63 MSEK

YoY

32.61%

Last updated:

In 2025, BibbInstruments's equity was 37.63 M SEK, a 32.61% increase from the 28.38 M SEK equity in the previous year.

The BibbInstruments Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
24.97 M SEK
Jan 1, 2019
28.42 M SEK
Jan 1, 2020
31.80 M SEK
Jan 1, 2021
21.53 M SEK
Jan 1, 2022
31.77 M SEK
Jan 1, 2023
31.22 M SEK
Jan 1, 2024
28.38 M SEK
Jan 1, 2025
37.63 M SEK
The BibbInstruments Equity history
YEAREquityYoY
37.63 MSEK+32.61%
28.38 MSEK-9.09%
31.22 MSEK-1.74%
31.77 MSEK+47.60%
21.53 MSEK-32.30%
31.80 MSEK+11.87%
28.42 MSEK+13.85%
24.97 MSEK+80.66%
13.82 MSEK+1,181.91%
1.08 MSEK+232.72%
324,000.00SEK+12.50%
288,000.00SEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BibbInstruments Stock analysis

What does BibbInstruments do? BibbInstruments AB is a specialized medical technology enterprise headquartered in Lund, Sweden, operating within the health care sector. The company focuses on the development and marketing of advanced diagnostic instruments designed for the early detection of cancerous tumors. BibbInstruments went public on the Stockholm Stock Exchange on October 27, 2017, under the ticker symbol BIBB.SL, with the associated ISIN SE0010102095. Despite its technological focus, the organization maintains a lean operational structure, currently employing only four full-time staff members. The core of the company’s innovation lies in its proprietary technology platform known as EndoDrill. This platform utilizes a unique drill function that facilitates early cancer diagnosis, particularly within deep skin tissues and internal organs, offering a minimally invasive alternative to traditional biopsy methods. The product portfolio is diverse and tailored to specific medical needs across various bodily systems. It includes the EndoDrill GI Upper, which is engineered for stomach biopsies, and the EndoDrill GI Lower, designed for intestinal procedures. For respiratory diagnostics, the company offers the EndoDrill GI Lung for lung biopsies. Beyond diagnosis, the portfolio extends into therapeutic applications through the EndoDrill Therapy device, which allows for the passage of displacements in different organs to facilitate the placement of conductors, balloons, and stents for treatment purposes. Additionally, the EndoDrill Needle is available for breast biopsies, while the EndoDrill Model X serves multiple areas and is currently part of an independent research project. The company’s distribution strategy is primarily concentrated on Scandinavian countries, targeting hospitals equipped with endoscopy specialist centers and surgical wards. By focusing on these specific clinical environments, BibbInstruments aims to provide healthcare professionals with precise tools that enhance diagnostic accuracy and patient outcomes. The company’s website, https://www.bibbinstruments.com/, serves as the primary digital hub for information regarding its products and technological advancements. As a small but focused entity, BibbInstruments AB represents a niche player in the global medical device market, emphasizing innovation in early cancer detection through its specialized EndoDrill technology. BibbInstruments is one of the most popular companies on Eulerpool.

Equity Details

Analyzing BibbInstruments's Equity

BibbInstruments's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding BibbInstruments's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating BibbInstruments's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

BibbInstruments's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in BibbInstruments’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about BibbInstruments stock

The Equity of BibbInstruments is 37.63 M SEK in 2025.

The Equity of BibbInstruments changed from 28.38 M SEK to 37.63 M SEK, representing a 32.61% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity BibbInstruments since 2006 – with annual values, charts, and detailed analysis.

The Equity's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's BibbInstruments historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — BibbInstruments

All Key Metrics — BibbInstruments